Skip to content

Comparing the Effectiveness of Memantine and Donepezil on elderly with dementia

Comparing the Effectiveness of Memantine and Donepezil on the Cognitive Status of the elderly with vascular dementia

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190525043700N6
Enrollment
60
Registered
2024-05-29
Start date
2024-06-21
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vascular dementia. Vascular dementia

Interventions

Intervention 1: Patients in the memantine group are treated with memantine tablets 5 mg twice a day for one to two weeks, then 10 mg twice a day for up to 6 months. (From Actover pharmaceutical compan

Sponsors

Babol University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: Age > 65 y MMSE Score < 24 + Evidence of metabolic disease Evidence in favor of vascular dementia in MRI

Exclusion criteria

Exclusion criteria: Patients with psychotic disorders Intellectual disability Patients who are already being treated for cognitive disorders Confirmed history of bipolar disorder or depression Patients with Alzheimer's and other neurological diseases

Design outcomes

Primary

MeasureTime frame
Investigating the cognitive status by comparing the MMSE and Edenbrook test results at the beginning, during the treatment and at the end of the treatment. Timepoint: At the beginning of work, 3 months and 6 months after the start of treatment. Method of measurement: Through the Eden Brook test.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Romina hamzehpour

Babol University of Medical Sciences

R.hamzehpour@mubabol.ac.ir+98 11 3222 3594

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026